BASEL LIFE 2019

9–12 September 2019

Congress Center Basel
Switzerland

Aging, Drug Discovery & Artificial Intelligence

Date

Tuesday & Thursday, 10-12 September 2019

Chairs

Alex Zhavoronkov (InSilico Medicine, Baltimore, United States)
Morten Scheibye-Knudsen (Danish Center for Aging Research/National Institute on Aging, Copenhagen, Denmark)

Abstract

In this symposium, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the forum will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. This event intends to bridge academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. A panel of thought-leaders will give us their cutting edge reports on the latest progress in our quest to extend the healthy lifespan of everyone on the planet. Please join us in this merger of driven scientists and global visionaries in an event that may shape the field in years to come.

Tuesday, 10 September 2019

10.00 – 16.30

10.00
Exploiting Aging Pathways to extend healthspan’
Dr. Brian Kennedy (NUS, Singapore, SG)


10.20
Mitochondrial Metabolic Checkpoint, Stem Cell Aging and Rejuvenation
Dr. Danica Chen (University of California, Berkeley, USA)

10.40
"Translational geroscience: A new paradigm for 21st Century Medicine"
 
Dr. Matt Kaeberlein (University of Washington, Seattle, USA)

11.00
Break

11.30
Rejuvenation biotechnology: why age may soon cease to mean aging
Dr. Aubrey de Grey (AgeX / SENS Research Foundation, London, UK)

11.50
Translational Strategies to Prevent Sarcopenia through Targeted Cellular Nutrition
Dr. Jerome Feige (Nestle Research, Lausanne, CH)

12.10
C/EBPβ transcription factors in health- and lifespan determination
Dr. Cornelis F. Calkhoven (ERIBA, University of Groningen, Groningen, NL)

12.45
Lunch Break & Industry Symposia

14.00
Drivers of neurotoxicity in prion diseases
Dr. Adriano Aguzzi (University of Zurich, Zurich, CH)

14.20
Leucine signals to mTORC1 via its metabolite acetyl-coenzyme APhD, FMedSci
Professor David Rubinsztein (Cambridge Institute for Medical Research, Cambridge, UK)

14.40
Convergent mechanisms of longevity
Dr. Adam Antebi (Max Planck Institute for Biology of Ageing, Cologne, DE)

15.00
Break

15.30
Impact of food perception on proteostasis & aging

Dr. Thorsten Hoppe (University of Cologne, Cologne, DE)

15.50
The art of decision-making by stem cells in the aging brain
Dr. Ana Martin- Villalba (DKFZ, Heidelberg, DE)

16.10
Power and benefit of selective phosphatase inhibition for neurodegenerative diseases
Dr. Anne Bertolotti (MRC Laboratory of Molecular Biology, Cambridge, UK)

 

 

Room Sydney

Wednesday, 11 September 2019

10.00-15.30

10.00
Mechanisms of intracellular DNA sensing through the cGAS-STING pathway
Dr. Andrea Ablasser (EPFL, Lausanne, CH)

10.20
Pandomics: a drug discovery tool for aging and oncology
Dr. Ivan Ozernov (Insilico Medicine, Hong Kong, CN)

10.40
From Longevity Signatures to Longevity Interventions

Dr. Vadim Gladyshev (Harvard Medical School, Boston, USA)

11.00
Break

11.30
Protecting the Aging Genome
Dr. Morten Scheibye-Knudsen (Center for Healthy Aging, Copenhagen, DK)

11.50
How to obtain an indication that targets health span
Dr. Nir Barzilai (Albert Einstein College, New York, USA)

12.10
Is anti-aging drug discovery becoming a reality
Dr. Alexey Moskalev (Engelhardt Institute of Molecular Biology, Moscow, RU) 

12.20
Identification and application of gene expression signatures associated with lifespan extension
Dr. Alexander Tyshkovskiy (Harvard Medical School, Boston, USA)

12.45 
Lunch Break & Industry Symposia


14.00
Targeting of stem cell niche produced Notum increases repair of old tissue
Dr. Pekka Katajisto (University of Helsinki, Helsinki, FL)

14.20
Making aging biology part of drug development
Martin Borch Jensen (Gordian Biotechnology, San Francisco, USA)

14.40
Panel discussion

15.00
Break

15.30
EMBO Plenary session 5: Regenerative medicine (on Aging)


Room Sydney

15.30-17.40

EMBO Plenary session 5: Regenerative medicine (on Aging)

Room Montreal

Thursday, 12 September 2019

09.00-10.15

Plenary session 6 (Joint with [BC]2) Computational biology, artificial intelligence, machine learning in precision medicine

Room Montreal

10.45-15.30

10.45
Deep learning in drug discovery for aging research
Dr. Quentin Vanhaelen (Insilico Medicine, Hong Kong, CN)

11.05
Combining robotics and AI to produce next generation research data
Dr. Martin-Immanuel Bittner (Arctoris, Oxford, UK)

11.25
Molecule: A novel approach to funding research and development through distributed IP ownership
Tyler Golato (Wildwood, US) 

11.45
Break

12.00
Passing the baton from academia to industry: therapies for thymus regeneration and atherosclerosis reversal
Reason (Repair Biotechnologies, Inc, Syracuse, NY, United States)

12.20
Ketogenic diet to delay brain aging in Cockayne syndrome
Michael A. Petr (University of Copenhagen, Copenhagen, DK)

12.40
Retrobiome’ as a driver of intrinsic DNA damage in aging
Dr. Andrei Gudkov (Roswell Park Cancer Institute, Buffalo, United States)

13.00
Lunch Break & Industry Symposia

14.30
Study of skin and face features age progression with computer vision methods
Anastasia Georgievskaya (Hait.AI, Tallinn, EE) 

14.50
Conquering Aging: AI Opportunity for the Pharmaceutical Industry
Dr. Unmesh Lal (Frost & Sullivan, DE)

15.00
Longevity VC panel
Unmesh Lal (Frost&Sullivan) – moderator
Cecile Cai (36KR )
Dmitry Kaminsky (Deep Knowledge Ventures, London UK)
Caleb Culverwell (Barclays, London, UK)
Michael Antonov (Oculus, San Francisco)
Patrick Burgermeister
(Kizoo Technology Capital, Karlsruhe, DE)
Angela Tyrrell (Longevity Leaders)

 

 

 

Room Sydney